|
Market Closed -
Other stock markets
|
After hours 18:44:11 | |||
| 84.16 EUR | +1.01% |
|
84.18 | +0.02% |
| 10:40am | Nurix Therapeutics Fiscal Q2 Loss Narrows, Revenue More Than Triples; Shares Surge Premarket | MT |
| 07-08 | SANOFI : UBS maintains a Buy rating | ZD |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- SAN Stock
- Consensus Sanofi
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition